FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE REV. 2/01T			ERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES				04914.0055-00000	
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A				U.S. APPLICATION NO.	
		FILING UNDE	R 35 U.S.C. 371	(If known, see 37CFR1.5)	
			·	10/595,546	
INTERNATIONAL APPLICATION NO.			INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
PCT/EP2004/012528			November 5, 2004	November 7, 2003	
TITLE OF INVENTION: INTEGRATED BLOOD TREATMENT MODULE					
APPLICANTS FOR DO/EO/US: Jürgen DANNENMAIER et al.					
Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C 371.			
2.	$\boxtimes$	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.			
4.		The US has been elected by the expiration of 19 months from the priority date (Article 31).			
5.		A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).			
		a.  is attached hereto (required only if not communicated by the International Bureau.			
		b.  has be	en communicated by the International Bureau.	·	
			required, as the application was filed with the U	•	
6.		An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).			
•		a. $\square$ is attac	ched hereto.		
	_		en previously submitted under 35 U.S.C. 154 (d		
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
		a. are attached hereto (required only if not communicated by the International Bureau).			
			een communicated by the International Bureau.		
3			ot been made; however, the time limit for making	ng such amendments has NO1 expired.	
		d. have not been made and will not be made.			
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).			
9.	Ø	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).			
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).			
Items 11 to 20 below concern document(s) or information included:					
items 11 to 20 below concern document(s) or into mation metaded.					
11.		Information Disclosure Statement under 37 CFR 1.97 and 1.98			
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13.		A FIRST preliminary amendment.			
14.	$\boxtimes$	A SECOND or SUBSEQUENT preliminary amendment.			
15.		A Substitute specification.			
16.	$\boxtimes$	A change of power of attorney and/or address letter.			
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.			
18.		A second copy of the published international application under 35 U.S.C. 154 (d)(4).			
19.		A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).			
20.	$\boxtimes$	Other items or information:			
		·	of cover page of International Publication No. V	vo ·	
		b. 🛛 Copy	of Notification of Missing Requirements.		